0001437749-24-003016.txt : 20240202
0001437749-24-003016.hdr.sgml : 20240202
20240202190736
ACCESSION NUMBER: 0001437749-24-003016
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240131
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schoenberg Mark
CENTRAL INDEX KEY: 0001763581
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38079
FILM NUMBER: 24593458
MAIL ADDRESS:
STREET 1: C/O UROGEN PHARMA LTD.
STREET 2: 9 HA TA ASIYA STREET
CITY: RA ANANA
STATE: L3
ZIP: 4365007
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: UroGen Pharma Ltd.
CENTRAL INDEX KEY: 0001668243
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9 HA'TA'ASIYA ST
CITY: RA'ANANA
STATE: L3
ZIP: 4365007
BUSINESS PHONE: 972 9 770 7601
MAIL ADDRESS:
STREET 1: 9 HA'TA'ASIYA ST
CITY: RA'ANANA
STATE: L3
ZIP: 4365007
4
1
rdgdoc.xml
FORM 4
X0508
4
2024-01-31
0001668243
UroGen Pharma Ltd.
URGN
0001763581
Schoenberg Mark
400 ALEXANDER PARK DRIVE
PRINCETON
NJ
08540
1
Chief Medical Officer
0
Ordinary Shares
2024-01-31
4
M
0
2000
A
150560
D
Ordinary Shares
2024-01-31
4
S
0
1137
15.74
D
149423
D
Ordinary Shares
2024-01-31
4
M
0
1333
A
150756
D
Ordinary Shares
2024-01-31
4
S
0
758
15.74
D
149998
D
Ordinary Shares
2024-01-31
4
M
0
3333
A
153331
D
Ordinary Shares
2024-01-31
4
S
0
1894
15.74
D
151437
D
Restricted Stock Units
2024-01-31
4
M
0
2000
0
D
Ordinary Shares
2000
0
D
Restricted Stock Units
2024-01-31
4
M
0
1333
0
D
Ordinary Shares
1333
1334
D
Restricted Stock Units
2024-01-31
4
M
0
3333
0
D
Ordinary Shares
3333
6667
D
Restricted Stock Units
2024-01-31
4
A
0
10000
0
A
Ordinary Shares
10000
10000
D
Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.
The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023.
The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.
1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027.
/s/ Jason D. Smith, Attorney-in-Fact
2024-02-02